Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumati Gupta

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|December 3, 2020
SITC cancer immunotherapy resource document: a compass in the land of biomarker discoverySiwen Hu-Lieskovan, Srabani Bhaumik, Kavita Dhodapkar, et al.
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Petros Grivas, Damien Pouessel, Chandler H Park, et al.
Clinical Proteomics|April 18, 2025
Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancerHyejung Lee, Jincheng Shen, Muhammad Zaki Fadlullah, et al.
Cancer|March 26, 2020
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA resultsSumanta K Pal, Dean Bajorin, Nazli Dizman, et al.
Cancer|December 21, 2018
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesPetros Grivas, Amir Mortazavi, Joel Picus, et al.
JCO Precision Oncology|July 8, 2024
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor GenomicsWendy Kohlmann, David A Nix, Kristen Pauley, et al.
NPJ Precision Oncology|January 12, 2026
ShinyEvents: harmonizing longitudinal data for real-world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
Research Square|August 13, 2025
ShinyEvents: harmonizing longitudinal data for real world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|December 3, 2020
SITC cancer immunotherapy resource document: a compass in the land of biomarker discoverySiwen Hu-Lieskovan, Srabani Bhaumik, Kavita Dhodapkar, et al.
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2024
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3Petros Grivas, Damien Pouessel, Chandler H Park, et al.
Clinical Proteomics|April 18, 2025
Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancerHyejung Lee, Jincheng Shen, Muhammad Zaki Fadlullah, et al.
Cancer|March 26, 2020
Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA resultsSumanta K Pal, Dean Bajorin, Nazli Dizman, et al.
Cancer|December 21, 2018
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genesPetros Grivas, Amir Mortazavi, Joel Picus, et al.
JCO Precision Oncology|July 8, 2024
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor GenomicsWendy Kohlmann, David A Nix, Kristen Pauley, et al.
NPJ Precision Oncology|January 12, 2026
ShinyEvents: harmonizing longitudinal data for real-world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerMatthew D Galsky, Amir Mortazavi, Matthew I Milowsky, et al.
Research Square|August 13, 2025
ShinyEvents: harmonizing longitudinal data for real world survival estimationAlyssa Obermayer, Joshua Davis, Divya Priyanka Talada, et al.
Pageof 7